-+ 0.00%
-+ 0.00%
-+ 0.00%

UroGen Pharma Announces 36-Month Duration Of Response By Kaplan-Meier Estimate In Patients Who Achieved Complete Response At Three Months In Pivotal Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution.

Benzinga·05/13/2026 12:09:44
Listen to the news
  • 64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months
    • First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer